Lymphoma News

A novel chimeric antigen receptor T-cell therapy induced response among adults with advanced large B-cell lymphoma who relapsed after previous CAR-T, study results showed.

Patients who received chimeric antigen receptor T cells for relapsed or refractory diffuse large B-cell lymphoma feared disease progression less than those who received standard regimens, results of a cross-sectional study showed.

The FDA recently withdrew its emergency use authorization for Evusheld, a combination monoclonal antibody therapy used to prevent COVID-19 among high-risk individuals.

A remote dietary intervention was feasible and reduced chronic fatigue among lymphoma survivors, according to researchers.

High BMI appeared associated with increased risk for any-grade immune-related adverse events among a cohort of patients with advanced cancer undergoing treatment with immune checkpoint inhibitors.

Researchers at Cold Spring Harbor Laboratory have developed software that correctly deduces continental ancestry from tumor DNA and RNA.

World Cancer Day is observed annually on Feb. 4.

Women with diffuse large B-cell lymphoma experienced significantly longer PFS and OS when receiving chemotherapy in the afternoon compared with the morning, according to data published in JCI Insight.

NEW ORLEANS — Health-related quality of life in patients with diffuse large B-cell lymphoma improved in a comparison of two therapy regimens.

Patient withdrawal from cancer clinical trials can result in systematic bias, insufficiently powered studies and a loss of valuable scientific knowledge, according to a study in JAMA Network Open.